Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Hansoh Pharma's EGFR-Mutated Lung Cancer Drug Gains Market Authorization in China

Hansoh Pharma's EGFR-Mutated Lung Cancer Drug Gains Market Authorization in China

Mar 19, 2020
|
staff reporter

NEW YORK – China-based

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Cancer

  1. NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

  2. Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

  3. BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

  4. Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing

    Premium

  5. Full BRCA1 Gene Deletion Suspected to Contribute to Patient's Long PARP Inhibitor Response

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.